DB:H2K2

Stock Analysis Report

Executive Summary

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has XTL Biopharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: H2K2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

19.1%

H2K2

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-53.6%

H2K2

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: H2K2 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: H2K2 underperformed the German Market which returned -17.7% over the past year.


Shareholder returns

H2K2IndustryMarket
7 Day19.1%11.2%7.3%
30 Day-24.6%-5.3%-17.9%
90 Day-18.5%-21.9%-25.8%
1 Year-53.6%-53.6%-4.9%-5.1%-15.1%-17.7%
3 Year-61.8%-61.8%17.7%16.5%-18.7%-25.6%
5 Year-91.1%-91.1%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is XTL Biopharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is XTL Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.91x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate H2K2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate H2K2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: H2K2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: H2K2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate H2K2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: H2K2 is good value based on its PB Ratio (0.9x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is XTL Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XTL Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has XTL Biopharmaceuticals performed over the past 5 years?

48.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: H2K2 is currently unprofitable.

Growing Profit Margin: H2K2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: H2K2 is unprofitable, but has reduced losses over the past 5 years at a rate of 48.9% per year.

Accelerating Growth: Unable to compare H2K2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: H2K2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: H2K2 has a negative Return on Equity (-19.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is XTL Biopharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: H2K2's short term assets ($6.8M) exceed its short term liabilities ($232.0K).

Long Term Liabilities: H2K2 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: H2K2 is debt free.

Reducing Debt: H2K2 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: H2K2 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if H2K2's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if H2K2 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if H2K2 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is XTL Biopharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate H2K2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate H2K2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if H2K2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if H2K2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of H2K2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average board tenure


CEO

Doron Turgeman (51yo)

0.17

Tenure

Mr. Doron Turgeman has been Chief Executive Officer at XTL Biopharmaceuticals Ltd. since January 29, 2020. Mr. Turgeman has been the Chief Executive Officer of Internet Gold Golden Lines Ltd. Mr. Turgeman  ...


Board Members

NamePositionTenureCompensationOwnership
Doron Turgeman
Chairman & CEO0.17yrno data0.095% $5.1k
Shlomo Shalev
Director5.25yrsno datano data
Lee Simon
Member of Clinical Advisory Boardno datano datano data
Daniel Wallace
Member of Clinical Advisory Boardno datano datano data
Jonathan Schapiro
Non-Executive Director5.25yrsno datano data
Dobroslav Melamed
Non-Executive Director5.25yrsno datano data
Murray Urowitz
Member of Clinical Advisory Boardno datano datano data
Osnat Fain
Non-Executive & External Director5yrsno datano data
David Isenberg
Member of Clinical Advisory Board4.5yrsno datano data
Robert Fox
Member of Clinical Advisory Board3yrsno datano data

5.0yrs

Average Tenure

55yo

Average Age

Experienced Board: H2K2's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

XTL Biopharmaceuticals Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: XTL Biopharmaceuticals Ltd.
  • Ticker: H2K2
  • Exchange: DB
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₪21.082m
  • Listing Market Cap: ₪5.320m
  • Shares outstanding: 514.21m
  • Website: https://www.xtlbio.com

Number of Employees


Location

  • XTL Biopharmaceuticals Ltd.
  • 5 Badner Street
  • Ramat Gan
  • 4365603
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
H2K2DB (Deutsche Boerse AG)SPON ADR EACH REP 100 ORD SHS(POST SPLT)DEEURNo data
XTLBTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSSep 2000
XTLBNasdaqCM (Nasdaq Capital Market)SPON ADS EACH REP 100 ORD SHS(POST SPLT)USUSDSep 2005
H2K2DB (Deutsche Boerse AG)SPON ADS EACH REP 100 ORD SHS(POST SPLT)DEEURSep 2005

Biography

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 21:31
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.